Liminal BioSciences Inc. PFSCF

Primary Symbol: LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc.

Bullboard Posts

Comment by biggerron Oct 16, 2018 5:46pm

149 Views

Post# 28813898

RE:Paradigm Capital: Buy rating and $1.50 target price for PLI

since Ryplazim is as good as approved and only 6 months delayed the $1.50 SP sure makes sense already since PLI was at this level when FDA delayed the initial BLA in March

Bullboard Posts

Canada Nickel unveils second of seven resources planned by mid-2025